New Clinical Research Validates Efficacy of GammaTile for Treating Recurrent Brain Metastases

On September 11, 2025, GT Medical Technologies unveiled enlightening clinical research affirming the efficacy of GammaTile® in the latest edition of the Journal of Neuro-Oncology. The study, titled "Cesium-131 Collagen Tile Brachytherapy for Salvage and Recurrent Intracranial Metastases," was conducted by researchers at MD Anderson Cancer Center and focuses on encouraging treatment outcomes for patients with recurrent brain metastases who have previously undergone tumor removal and external beam radiation therapy (EBRT).

Understanding GammaTile®

GammaTile is a bioabsorptive collagen implant embedded with cesium-131 radiation seeds. This innovative device offers immediate, localized radiation delivery during the surgical extraction of a tumor. Positioned at the recurrence-prone site, GammaTile operates from within the body, providing continuous treatment throughout a patient's recovery. This feature aims to heal the treatment gap that often exists between surgical intervention and subsequent radiation therapy.

Brain metastases that recur post-treatment can be complicated due to the limitations of prior radiation doses and the heightened threat of radiation toxicity affecting healthy brain cells. Luckily, advancements in systemic therapy are allowing patients with metastatic diseases to survive longer than before, raising the necessity for effective local control of brain tumors.

Study Insights

The study involved 31 patients with a total of 38 tumors, previously treated with stereotactic radiosurgery (SRS), who underwent salvage resection using GammaTile. The findings revealed a local failure incidence of just 13% after one year. This figure dropped to 6.4% for tumors where full resection had been achieved prior to GammaTile implantation. Consequently, about 87% of patients, and 94% of those with gross total resection, maintained local tumor control at the one-year mark, all while experiencing a remarkably low rate of symptomatic radiation toxicity of only 8%.

These results represent a significant enhancement when juxtaposed against historical data. Traditional recurrence rates after simple tumor resection hover around 40% at the one-year benchmark, while resection complemented by repeat SRS typically yields only 71-75% control, often accompanied by heightened toxicity. In comparison, GammaTile boasts an impressive local control rate of 80-100% at one year and maintains minimal toxicity levels.

Clinical Momentum

This peer-reviewed research from MD Anderson underscores the mounting data that supports GammaTile's use, following similar findings from a Miami Cancer Institute study. That research determined that GammaTile effectively administers a higher therapeutic dose directly to the surgical cavity, minimizing radiation exposure to adjacent healthy brain tissue versus the SRS methods. Collectively, these studies underscore GammaTile's clinical strength and distinctive dosimetric benefits, suggesting that it could revolutionize the treatment protocols for recurrent brain metastases.

Dr. Michael Garcia, Chief Medical Officer of GT Medical Technologies, emphasized, “Patients with recurrent brain metastases often have few options available due to prior radiation. These findings confirm that GammaTile offers lasting local control with low toxicity despite previous treatments.”

About GT Medical Technologies

Established by a passionate group of brain tumor specialists, GT Medical Technologies aims to resolve unaddressed needs in brain tumor treatment. They remain devoted to enhancing the lives of patients with brain tumors via innovative technologies that elevate treatment standards.

About GammaTile

GammaTile is an FDA-approved, bioabsorbable collagen implant embedded with radiation seeds specifically designed for patients undergoing operable brain tumor surgeries. With its targeted radiation delivery from within the body—once implanted in the surgical cavity during tumor resection—GammaTile facilitates immediate and localized treatment aimed at preventing cancer cell regrowth and minimizing radiation exposure to healthy tissue.

Since its official market launch in the United States in March 2020, GammaTile has captured the attention of over 100 leading medical institutions, marking its acceptance in both academic and community healthcare environments.

For further details, visit gammatile.com and follow @GammaTile on social media platforms.

References

1. Garcia MA et al. J Neurooncol. 166203-212 (2024).
2. Imber BS, et al. J Neurooncol. 159(3)609-618 (2022).
3. Beckham TH, Cha EE, Rooney MK, et al. J Neurooncol (2025).
4. Kutuk T, et al. Brachytherapy. 22(6)872-881 (2023).
5. Nakaji P, et al. Cureus. 12(11)e11570 (2020).
6. Buszek SM, et al. Pract Radiat Oncol. 13e499-e503 (2023).
7. Wilcox JA, et al. J Neurooncol. 155277-286(2021).
8. Holt DE, et al. Front Oncol. 584 (2015).
9. Kutuk T, et al. Brachytherapy. 23(6)751-760 (2024).